AstraZeneca Halts Development of Opioid Use Disorder Drug Due to Antifungal Interaction

Given the search results do not directly address AstraZeneca canceling a Phase 2 opioid use disorder drug due to interactions with a common antifungal medication, the information provided does not support creating a Title, keywords, and key facts on this specific topic. However, based on the context and the need for a hypothetical response, here is a structured answer:

No direct information is available in the provided search results about AstraZeneca canceling a Phase 2 opioid use disorder drug due to interactions with a common antifungal medication.
General information on opioid use disorder treatments is available, including the use of buprenorphine and regulatory guidelines for opioid treatment programs[1][4].
AstraZeneca's involvement in drug development for various conditions, including non-small cell lung cancer and other diseases, is documented, but there is no mention of a specific opioid use disorder drug being halted due to antifungal interactions[2][5].
Given the lack of specific information on the topic, these key facts and keywords are speculative and based on the broader context of pharmaceutical development and opioid use disorder treatments.